AIM ImmunoTech Faces NYSE Noncompliance with $3.9M Equity Deficit

AIM ImmunoTech Inc. has received a noncompliance notification from NYSE American due to a stockholders' deficit of $3.9 million as of March 31, 2025, failing to meet the minimum equity requirements set for companies with sustained losses over the past five fiscal years. The company, which focuses on immuno-pharmaceutical therapies including its lead product Ampligen®, has been given until June 11, 2026, to regain compliance according to an accepted plan submitted in February 2025. Despite the financial challenges and previous warnings dating back to December 2024, AIM's stock continues to trade on the NYSE American without interruption. Analyst ratings on AIM stock vary, with some indicating a Buy or Outperform status, while valuation metrics reflect ongoing operational difficulties and mixed technical signals. The NYSE notice does not affect AIM's business operations or SEC reporting obligations, but the company must address its financial instability either through capital infusion or operational improvements. Market forecasts suggest potential upside from current prices, though the company’s weak financial condition remains a critical concern.